

The company has released voluntary disclosures since 2015 in accordance with the EFPIA Code of Practice

Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2021

- In line with its commitment to transparency, Grifols has disclosed for the seventh consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the EFPIA's scope, including Spain.
- In 2021, Grifols made transfers of value in Europe amounting to Euro 18.9 million. This 41% increase compared to 2020 is mainly due to two factors:
 1. Larger investments in studies related to, among other areas, the SARS-CoV-2 virus, which resulted in a 38% increase in transfers of value related to R&D compared to 2020. They amounted to Euro 15.6 million, representing 83% of the total.
 2. The progressive recovery of face-to-face interactions with healthcare organizations and healthcare professionals at scientific events, which have returned to similar pre-pandemic levels.
- These two factors also explain the evolution registered in Spain. Transfers of value increased 78% to Euro 12.9 million. Those related to R&D accounted for 94% of the total amount and stood at Euro 12.2 million.
- Spain generated 68% of the group's total transfers in Europe in 2021 and 78% of those related to R&D.
- In 2021, Grifols made transfers of value to 194 healthcare professionals in Spain that amounted to Euro 156,874 (Euro 153,425 in 2020) and 47 healthcare organizations, which totaled Euro 556,378 (Euro 436,969 in 2020).
- The *EFPIA Code of Practice*, which promotes transparency in industry interactions with healthcare professionals, healthcare organizations and patient organizations, applies specifically to medicines. Nonetheless Grifols expands its scope to include transfers unrelated to medications, as well as to all the company's divisions.
- In addition to Europe, Grifols applies this policy of transparency to the United States as required by the regulatory body (Centers for Medicare & Medicaid Services, CMS).
- All related information is public and available on the Grifols corporate website: www.grifols.com

Information Published in Accordance with the EFPIA Code of Practice

Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and healthcare organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.

Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and sponsorship agreements with healthcare organizations, as well as payments to third parties designated to manage the event on their behalf; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities; and payments and other transfers of value related to R&D activities.

Specifically, the code of conduct is applied in the following European countries: Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.

For investors:

Investor Relations and Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

For media inquiries:

Duomo Comunicacion Tel. +34 91 311 92 89 - 91 311 92 90 Raquel Lumbreras raquel_lumbreras@duomocomunicacion.com Tel. +34 659 57 21 85 Borja Gómez borja_gomez@duomocomunicacion.com Tel. +34 650 402 225	Grifols Press Office media@grifols.com Tel. +34 93 571 00 02
---	--

About Grifols

Grifols is a global company in the health sector that has been working since 1909 to improve the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.

A pioneer in the blood products industry, Grifols is one of the largest plasma companies, with a growing network of donation centers around the world. With the plasma obtained, Grifols produces essential medicines to treat chronic, rare and sometimes very serious diseases. As a recognized leader in transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from donation to transfusion. In addition, it provides hospitals, pharmacies and health professionals with the tools, information and services that contribute to offering specialized and efficient medical care.

GRIFOLS

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that helps define the standards of continuous innovation, quality, safety and ethical leadership in the sector.

In 2021, Grifols' total economic impact in the main countries where it operates is estimated at 7,700 million euros and 141,500 jobs generated, including direct, indirect and induced jobs.

The company's ordinary shares (Class A) are listed on the Spanish Continuous Market and form part of the Ibex-35 (MCE: GRF). Grifols non-voting shares (Class B) are listed on the Spanish Continuous Market (MCE: GRF.P) and on the North American NASDAQ through ADR (American Depositary Receipts) (NASDAQ: GRFS).

For more information: www.grifols.com



LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.